@article{3105429,
    title = "The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort",
    author = "Radin, M. and Sciascia, S. and Erkan, D. and Pengo, V. and Tektonidou, M.G. and Ugarte, A. and Meroni, P. and Ji, L. and Belmont, H.M. and Cohen, H. and Ramires de Jesús, G. and Branch, D.W. and Fortin, P.R. and Andreoli, L. and Petri, M. and Rodriguez, E. and Rodriguez-Pinto, I. and Knight, J.S. and Atsumi, T. and Willis, R. and Gonzalez, E. and Lopez-Pedrera, R. and Rossi Gandara, A.P. and Borges Gualhardo Vendramini, M. and Banzato, A. and Sevim, E. and Barbhaiya, M. and Efthymiou, M. and Mackie, I. and Bertolaccini, M.L. and Andrade, D.",
    journal = "Seminars in Arthritis and Rheumatism",
    year = "2019",
    volume = "49",
    number = "3",
    pages = "464-468",
    publisher = "W.B. Saunders",
    issn = "0049-0172",
    doi = "10.1016/j.semarthrit.2019.04.009",
    keywords = "beta2 glycoprotein 1 antibody;  phospholipid antibody;  biological marker;  phospholipid antibody, adjusted global antiphospholipid syndrome score;  adult;  antiphospholipid syndrome;  Article;  cardiovascular risk;  clinical assessment;  comparative study;  controlled study;  cross-sectional study;  female;  human;  hyperlipidemia;  hypertension;  major clinical study;  male;  medical history;  middle aged;  priority journal;  recurrence risk;  recurrent disease;  thrombosis;  antiphospholipid syndrome;  blood;  clinical trial;  complication;  follow up;  global health;  immunology;  multicenter study;  procedures;  prognosis;  register;  retrospective study;  risk assessment;  risk factor;  severity of illness index;  thrombosis, Antibodies, Antiphospholipid;  Antiphospholipid Syndrome;  Biomarkers;  Cross-Sectional Studies;  Female;  Follow-Up Studies;  Global Health;  Humans;  Male;  Middle Aged;  Prognosis;  Recurrence;  Registries;  Retrospective Studies;  Risk Assessment;  Risk Factors;  Severity of Illness Index;  Thrombosis",
    abstract = "Objectives: To assess whether patients with antiphospholipid syndrome (APS) and history of recurrent thrombosis have higher levels of adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) when compared to patients without recurrent thrombosis. Methods: In this cross-sectional study of antiphospholipid antibody (aPL)-positive patients, we identified APS patients with a history of documented thrombosis from the AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”). Data on aPL-related medical history and cardiovascular risk factors were retrospectively collected. The aGAPSS was calculated at Registry entry by adding the points corresponding to the risk factors: three for hyperlipidemia, one for arterial hypertension, five for positive anticardiolipin antibodies, four for positive anti-β2 glycoprotein-I antibodies and four for positive lupus anticoagulant test. Results: The analysis included 379 APS patients who presented with arterial and/or venous thrombosis. Overall, significantly higher aGAPSS were seen in patients with recurrent thrombosis (arterial or venous) compared to those without recurrence (7.8 ± 3.3 vs. 6 ± 3.9, p<0.05). When analyzed based on the site of the recurrence, patients with recurrent arterial, but not venous, thrombosis had higher aGAPSS (8.1 ± SD 2.9 vs. 6 ± 3.9; p<0.05). Conclusions: Based on analysis of our international large-scale Registry of aPL-positive patients, the aGAPSS might help risk stratifying patients based on the likelihood of developing recurrent thrombosis in APS. © 2019 Elsevier Inc."
}